"Thanks for the review....however DM expected something to happen back then like an Esperion sale....but the trajectory of the two companies found a far different path."

Yes, back then RVX-208 was thought to simply be a drug that stimulated apo-AI/HDL production. And back then Esperion's lead drug was an injectable version of apo-AI. Fast forward, we now know that apabetalone (RVX-208) is a BET bromodomain inhibitor with many functions beyond apo-AI/HDL, and Esperion is re-born with an entirely new drug and indication (LDL-C lowering).

Keep in mind that the HDL hypothesis took a huge hit with the CETP drug failures.

BDAZ